A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)

NCT06980805 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus

Interventions

DRUG: IMVT-1402
DRUG: Placebo

Sponsor

Immunovant Sciences GmbH